CYP2D6*10基因多态性与他莫昔芬不良反应关联研究
该研究纳入177例激素受体阳性术后服用他莫昔芬的乳腺癌患者,检测CYP2D6*10基因型并随访不良反应。CT+TT基因型组子宫内膜增厚较CC组更明显,差异有统计学意义(P<0.01);肝功能异常、脂肪肝、子宫肌瘤等风险差异无统计学意义。
要点
- 177例中CC型40例(22.6%)、CT型79例(44.6%)、TT型58例(32.8%)。
- CT+TT型子宫内膜增厚(4.37±3.82)mm,较CC型(2.43±2.96)mm更明显(P<0.01)。
- 肝功能异常、脂肪肝、子宫肌瘤、复发转移风险两基因型间差异均无统计学意义(均P>0.05)。
核心结论
- 他莫昔芬是绝经前激素受体阳性乳腺癌内分泌治疗的主要药物,其疗效受CYP2D6*10多态性影响。
- CYP2D6*10基因多态性与他莫昔芬治疗后子宫内膜增厚程度有关,携带CT和TT基因型者增厚更明显。
- 作者建议对携带CYP2D6 CT和TT基因型的乳腺癌患者,他莫昔芬治疗期间加强子宫内膜监测并及时调整用药。
研究设计与样本
- 2012年11月至2021年12月南京医科大学第一附属医院收治的177例激素受体阳性且术后服用他莫昔芬的乳腺癌患者。
- 收集临床病理资料,随访他莫昔芬治疗相关不良反应;治疗2年后取指血行CYP2D6基因多态性检测。
- 利用RNAfold、QTLbase、3DSNP v2.0、RegulomeDB 2.2和HaploReg v4.2数据库注释CYP2D6多态性位点与调控元件的近端及远端相互作用。
主要发现
- 基因型分布为CC型40例(22.6%)、CT型79例(44.6%)、TT型58例(32.8%)。
- 常见不良反应包括肝功能异常58例、脂肪肝81例、子宫肌瘤12例、因子宫内膜增厚行子宫内膜手术17例。
- 单因素和多因素logistic回归显示,CT+TT型相对于CC型出现肝功能异常、脂肪肝、子宫肌瘤、因子宫内膜增厚行子宫内膜手术的风险差异均无统计学意义(均P>0.05)。
- CT+TT基因型组子宫内膜增厚(4.37±3.82)mm,较CC基因型组(2.43±2.96)mm更明显,差异有统计学意义(P<0.01)。
- eQTL分析显示,CYP2D6 rs1065852不同基因型的乳腺组织中CYP2D6表达水平差异有统计学意义(P<0.01)。
临床怎么用
- 作者建议对携带CYP2D6 CT和TT基因型的乳腺癌患者,在他莫昔芬治疗期间加强子宫内膜监测并及时调整用药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: We aimed to investigate the relationship between CYP2D6*10 gene polymorphisms and adverse reactions associated with tamoxifen treatment in breast cancer patients, and assess the value of CYP2D6*10 gene polymorphism testing in guiding the use of medications in endocrine therapy for breast cancer. Methods: 177 breast cancer patients with HR-positive and postoperative tamoxifen were admitted to the First Affiliated Hospital of Nanjing Medical University from November 2012 to December 2021. Their clinicopathologic data were collected for follow-up observation of adverse reactions related to tamoxifen treatment. After two years of tamoxifen treatment, finger blood of these patients was taken for CYP2D6 gene polymorphism detection. Moreover, databases including RNAfold, QTLbase, 3DSNP v2.0, RegulomeDB 2.2, and HaploReg v4.2 were used to predict the annotation of proximal and distal interactions of CYP2D6 polymorphic sites between genes and regulatory elements. Results: Genotyping analysis revealed 40 patients (22.6%) with the CC genotype, 79 (44.6%) with the CT genotype, and 58 (32.8%) with the TT genotype. Common adverse reactions to tamoxifen included abnormal liver function (58), fatty liver (81), uterine fibroids (12), and endometrial surgery for endometrial thickening (17). Univariate and multivariate logistic regression analyses showed that there were no significant statistical differences between the CC and CT+TT genotypes in terms of liver damage, new-onset fatty liver, uterine fibroids, or tumor recurrence and metastasis (P>0.05). Notably, endometrial thickening was more significant in patients with the CT+TT genotype (4.37±3.82 mm) than in those with the CC genotype (2.43±2.96 mm), with a statistically significant difference between them (P<0.01). Bioinformatic analysis suggested that in breast tissues, the CYP2D6*10 polymorphic locus had a significant expression quantitative trait locus (eQTL) effect with CYP2D6, and its genetic variations could affect the binding of CYP2D6 to transcription factors, which might modulate the expression of CYP2D6 through changes in secondary structure and chromatin modifications, etc., and thus affect the tamoxifen drug sensitivity. Further eQTL analysis showed significant correlation between CYP2D6 expression levels with different genotypes of the CYP2D6 rs1065852 polymorphism in breast tissues (P<0.01). Conclusion: Tamoxifen remains a primary therapeutic agent for premenopausal HR-positive breast cancer patients, and its efficacy is influenced by polymorphisms in the CYP2D6*10. It is recommended that for breast cancer patients carrying the CYP2D6 CT and TT genotypes, endometrial monitoring should be strengthened during treatment with tamoxifen, and the medication should be adjusted in a timely manner. 目的: 探讨CYP2D6*10基因多态性与乳腺癌患者他莫昔芬治疗相关不良反应的关系,评估CYP2D6*10基因多态性检测在指导乳腺癌内分泌治疗用药中的价值。 方法: 2012年11月至2021年12月南京医科大学第一附属医院收治的177例激素受体阳性且术后服用他莫昔芬的乳腺癌患者,收集其临床病理资料,随访观察他莫昔芬治疗相关不良反应。患者使用他莫昔芬治疗2年后,取指血进行CYP2D6基因多态性检测。利用RNAfold、QTLbase、3DSNP v2.0、RegulomeDB 2.2和HaploReg v4.2数据库注释CYP2D6多态性位点在基因和调控元件之间的近端及远端相互作用。 结果: 177例患者中,CC基因型40例(22.6%),CT基因型79例(44.6%),TT基因型58例(32.8%)。他莫昔芬常见不良反应包括肝功能异常(58例)、脂肪肝(81例)、子宫肌瘤(12例)、因子宫内膜增厚行子宫内膜手术(17例)。单因素和多因素logistic回归分析显示,CT+TT基因型乳腺癌患者相对于CC基因型患者出现肝功能异常、脂肪肝、子宫肌瘤、因子宫内膜增厚行子宫内膜手术的风险差异均无统计学意义(均P>0.05)。然而,服用他莫昔芬后,CT+TT基因型组患者的子宫内膜增厚[(4.37±3.82)mm]较CC基因型组[(2.43±2.96)mm]更明显,差异有统计学意义(P<0.01)。生物信息学分析显示,在乳腺组织中,CYP2D6*10多态性位点与CYP2D6存在显著的表达数量性状位点(eQTL)效应,其遗传变异可影响CYP2D6与转录因子的结合,可能通过二级结构的改变和染色质修饰等调控CYP2D6的表达,进而影响乳腺癌患者对他莫昔芬的药物敏感性。eQTL分析显示,CYP2D6*10基因多态性(rs1065852)不同基因型的乳腺组织中CYP2D6表达水平差异有统计学意义(P<0.01)。 结论: 他莫昔芬是绝经前激素受体阳性乳腺癌内分泌治疗的主要药物,CYP2D6*10基因多态性与他莫昔芬治疗后患者子宫内膜增厚程度有关,携带CYP2D CT和TT基因型的患者子宫内膜增厚更加明显,在使用他莫昔芬治疗时应加强对这类患者子宫内膜的监测,及时调整用药。.
引用
- Zhu QN, Wang RX. [Study on the association between CYP2D6*10 polymorphism and adverse reactions to Tamoxifen]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 40375591. doi:10.3760/cma.j.cn112152-20240613-00251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。